Zai Lab: Xacduro And ZL-1310 Drive Growth Narrative [Seeking Alpha]
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen's (AMGN) Risk-Reward Profile [Yahoo! Finance]
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy [Yahoo! Finance]
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Zai Lab (ZLAB) had its price target lowered by JPMorgan Chase & Co. from $39.00 to $32.00. They now have an "overweight" rating on the stock.